COMP <GO>
CME vs BAC // EV/EBITDA & P/E VALUATION
CME Group Inc. (NASDAQ) VS. Bank of America Corporation (NYSE) • 15-METRIC TALLY: CME 9
— BAC 5
▲ EV/EBITDA & P/E VALUATION LEADER: BAC
LAST: $303.14 (+2.27%) • MKT CAP: $106.10B
valuation
40.2x
LAST: $50.01 (-2.21%) • MKT CAP: $357.61B
valuation
30.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CME VS. BAC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CME | BAC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.50% | 2.50% | +1.00 | CME | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 40.2x | 30.2x | +10.00 | BAC | /valuation <GO> |
| Free Cash Flow Yield | 3.95% | 2.10% | +1.85 | CME | /fcf-yield <GO> |
| Operating Margin | 64.90% | 32.90% | +32.00 | CME | /operating-margins <GO> |
| Net Profit Margin | 62.50% | 27.00% | +35.50 | CME | /net-margins <GO> |
| Revenue Growth (YoY) | 6.40% | 6.80% | -0.40 | BAC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 3.71% | 0.00% | +3.71 | CME | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.55 | 0.45 | +0.10 | CME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | BAC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.4 | 27.7 | +37.73 | CME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.90 | +0.11 | CME | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.3x | 10.9x | +13.40 | BAC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.10B | $357.61B | -$251.51B | BAC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CME REV | BAC REV | CME GROSS % | BAC GROSS % | CME FCF | BAC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.52B | $113.10B | 44.0% | 44.0% | $4.19B | $7.52B |
| FY 2024 | $6.13B | $105.86B | 44.0% | 44.0% | $3.60B | -$13.57B |
| FY 2023 | $5.58B | $102.77B | 44.0% | 44.0% | $3.20B | $40.36B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CME // BETA 1.01
BAC // BETA 0.90